The Financial Times reports that Moderna (NASDAQ:MRNA) is pitching a price of $50 – 60 per course (assuming to EU officials) for COVID-19 vaccine mRNA-1273. If accurate, the cost will be above the agreed-upon price for Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) BNT162b2.
All three stocks are down fractions after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.